Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

Visit IR website
Sign-up for e-mail alerts

NASDAQ: CELG	
Last Trade:	109.41
Trade Time:	4:15 PM ET Dec 15, 2017
Change:	1.17 (1.081%)
Day Range	107.68 - 109.64
52-Week Range	94.55 - 147.17
Volume	10,411,486

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... (more)

Stock Performance

Press Releases [View all]

Dec 11, 2017
Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Dec 10, 2017
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting

Dec 7, 2017
Long-Term Efficacy Data from the Phase III GeparSepto Study in High Risk Early Breast Cancer Patients Treated with ABRAXANE® Vs. Solvent-Based Paclitaxel to Be Reported

Dec 5, 2017
Celgene Launches Celgene Cancer Care Links TM to Support Cancer Healthcare Capacity Building in Resource-Constrained Countries

Nov 21, 2017
Results from 282 Abstracts Including Celgene Therapies and Pipeline Compounds to Be Presented at the American Society of Hematology Annual Meeting (ASH)

Financials [View all]

Feb 10, 2017
Annual Report (10-K)

Apr 27, 2017
Proxy Statement (DEF 14A)

Oct 26, 2017
Quarterly Report (10-Q)

Jul 27, 2017
Quarterly Report (10-Q)

Apr 27, 2017
Quarterly Report (10-Q)